XTLB Stock Overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
XTL Biopharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪2.44 |
| 52 Week High | ₪4.99 |
| 52 Week Low | ₪0.75 |
| Beta | 1.03 |
| 1 Month Change | 134.62% |
| 3 Month Change | 190.48% |
| 1 Year Change | 92.13% |
| 3 Year Change | -24.57% |
| 5 Year Change | 5.17% |
| Change since IPO | -99.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| XTLB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.6% | -4.2% | -3.7% |
| 1Y | 92.1% | -2.0% | 20.5% |
Return vs Industry: XTLB exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: XTLB exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| XTLB volatility | |
|---|---|
| XTLB Average Weekly Movement | 42.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XTLB's share price has been volatile over the past 3 months.
Volatility Over Time: XTLB's weekly volatility has increased from 25% to 42% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Shlomo Shalev | www.xtlbio.com |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
XTL Biopharmaceuticals Ltd. Fundamentals Summary
| XTLB fundamental statistics | |
|---|---|
| Market cap | US$12.92m |
| Earnings (TTM) | -US$2.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs XTLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XTLB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.25m |
| Earnings | -US$2.25m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0041 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XTLB perform over the long term?
See historical performance and comparison